Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CING | US
0.43
11.94%
Healthcare
Biotechnology
30/06/2024
02/06/2026
4.03
3.58
4.93
3.54
Cingulate Inc. a clinical-stage biopharmaceutical company focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate) which is in phase 3 clinical trial and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children adolescents and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City Kansas.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
153.7%1 month
117.6%3 months
124.8%6 months
108.0%-
-
4.53
0.11
0.06
-0.36
-
-
-18.05M
12.27M
12.27M
-
-
-
-
-1.36K
0.05
0.95
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.99
Range1M
2.38
Range3M
8.73
Rel. volume
5.57
Price X volume
18.15M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 1.14 | 13.16M | -0.10% | n/a | 3.98% |
| Kezar Life Sciences Inc | KZR | Biotechnology | 0.18 | 13.13M | 5.88% | n/a | 11.69% |
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 2.39 | 13.10M | 8.64% | n/a | 268.29% |
| PLUR | PLUR | Biotechnology | 2.365 | 12.94M | -1.87% | n/a | 30845.83% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.1 | 12.91M | -2.33% | n/a | 54.59% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.42 | 12.67M | -6.58% | n/a | 0.00% |
| XTL Biopharmaceuticals Ltd | XTLB | Biotechnology | 2.29 | 12.48M | -4.58% | n/a | 0.00% |
| Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 2.25 | 12.03M | -1.32% | n/a | 0.00% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 0.76 | 10.91M | -1.30% | n/a | 11.72% |
| HOOKIPA Pharma Inc | HOOK | Biotechnology | 1.09 | 10.79M | -4.39% | n/a | 5.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4275 | 8.26M | -0.47% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.71 | 4.37M | 1.18% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0063 | 580.95K | 12.50% | n/a | -37.05% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4821 | 265.64K | -11.54% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.53 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 124.82 | - | Riskier |
| Debt to Equity | 0.11 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 12.27M | - | Emerging |